Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
Investigational New Drugs|May 26, 2023
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cellsMinhong Tang, John Crown, Michael J Duffy
International Journal of Cancer|May 15, 2012
Targeted therapy for triple-negative breast cancer: where are we?Michael J Duffy, Patricia M McGowan, John Crown
European Journal of Cancer (Oxford, England : 1990)|July 31, 2017
Mutant p53 as a target for cancer treatmentMichael J Duffy, Naoise C Synnott, John Crown
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 19, 2018
Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNAMichael J Duffy, Enda W McDermott, John Crown
Cancer Treatment Reviews|June 30, 2009
Survivin: a new target for anti-cancer therapyBríd M Ryan, Norma O'Donovan, Michael J Duffy
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 7, 2010
CA 15-3: uses and limitation as a biomarker for breast cancerMichael J Duffy, Denis Evoy, Enda W McDermott
Breast Cancer Research and Treatment|March 23, 2018
Mutant p53 in breast cancer: potential as a therapeutic target and biomarkerMichael J Duffy, Naoise C Synnott, John Crown
Annals of Clinical Biochemistry|July 13, 2011
The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratoryCatharine M Sturgeon, Michael J Duffy, Graeme Walker
Clinical Chemistry and Laboratory Medicine|April 15, 2021
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?Michael J Duffy, Eleftherios P Diamandis, John Crown
Breast Cancer Research and Treatment|July 30, 2022
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975Minhong Tang, Shane O'Grady, John Crown, et al.
Pageof 12